Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21384794 | 0.80 | MAPK1 (0.32) | KCNH2CYP11B1CYP11B2NR3C2 | |
| SCHEMBL31057602 | 0.78 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL18529102 | 0.78 | KCNH2 (0.32) | KCNH2 | |
| SCHEMBL31057590 | 0.76 | KCNH2 (0.30) | KCNH2 | |
| SCHEMBL18529063 | 0.76 | KCNH2 (0.30) | KCNH2 | |
| SCHEMBL18542847 | 0.76 | NR3C2 (0.34) | KCNH2NR3C2 | |
| SCHEMBL16651977 | 0.73 | MMP12 (0.33) | CYP11B1CYP11B2NR3C2 | |
| SCHEMBL21429876 | 0.72 | KCNH2 (0.39) | KCNH2NR3C2 | |
| SCHEMBL30306227 | 0.72 | KCNH2 (0.39) | KCNH2NR3C2 | |
| SCHEMBL30406269 | 0.72 | KCNH2 (0.35) | KCNH2NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724427-A1 | A PROCESS OF PREPARATION OF AN ANTIBACTERIAL COMPOUND AND ITS INTERMEDIATES THEREOF | Bugworks Research, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| WO-2024252423-A1 | A PROCESS OF PREPARATION OF AN ANTIBACTERIAL COMPOUND AND ITS INTERMEDIATES THEREOF | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2024-12-12 | — | — | WO | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| EP-3717490-B1 | ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS | BUGWORKS RES INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-11590142-B2 | Oxazolidinone antibiotic compounds and process of preparation | Bugworks Research, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3774790-B1 | OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3774790-B1 | OXAZOLIDINONE ANTIBIOTIC COMPOUNDS AND PROCESS OF PREPARATION | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3634968-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RES INC (US) | 2023-01-25 | — | — | EP | disclosed |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | Bugworks Research, Inc. (US) | 2022-08-02 | — | — | US | disclosed |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-10364254-B2 | Compounds for use in antibacterial applications | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| WO-2018225097-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS ANTI-BACTERIAL AGENTS AND METHOD FOR PRODUCTION THEREOF | BUGWORKS RESEARCH INDIA PVT LTD (IN) | 2018-12-13 | — | — | WO | disclosed |
| EP-3334739-A2 | ANTIBACTERIAL AGENTS COMPRISING A PYRAZINO[2,3-B][1,4]OXAZIN-3-ONE OR A RELATED RING SYSTEM | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017029602-A2 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017029602-A2 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270755-A1 | COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS | MRPL21, CFTR, NRDC | KCNH2 2823/4885AKR1B1 3853/4885CYP11B1 4652/4885 |
| US-11401277-B2 | Anti-bacterial heterocyclic compounds and their synthesis | HLA-B, BAX, REN | KCNH2 3099/4885AKR1B1 392/4885CYP11B1 10/4885 |
| US-11590142-B2 | Oxazolidinone antibiotic compounds and process of preparation | ALPI, OXA1L, ALPL | KCNH2 4322/4885AKR1B1 598/4885CYP11B1 39/4885 |
| US-20190031680-A1 | COMPOUNDS FOR US IN ANTIBACTERIAL APPLICATIONS | CFTR, MRPL21, CLPP | KCNH2 2998/4885AKR1B1 4327/4885CYP11B1 4802/4885 |
| US-10364254-B2 | Compounds for use in antibacterial applications | MRPL21, CFTR, NRDC | KCNH2 2823/4885AKR1B1 3853/4885CYP11B1 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.